Market research
ADMP Adamis Pharma
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 7M
- P/E ratio
- Not available
- Analyst target
- 0.42
- Dividend yield
- 0.0%
- Beta
- 1.28
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- US00547W2089
- Market cap
- 7M
- P/E ratio
- Not available
- Analyst target
- 0.42
- Dividend yield
- 0.0%
- Beta
- 1.28
About
About Adamis Pharma
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company is headquartered in San Diego, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ADMP discussion.
5 years, 4 months ago
Adamis Pharmaceuticals Corporation is currently in a long term uptrend where the price is trading 20.4% above its 200 day moving average.
From a valuation standpoint, the stock is 99.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.5.
Adamis Pharmaceuticals Corporation's total revenue sank by 27.1% to $4M since the same quarter in the previous year.
Its net income has dropped by 6.9% to $-7M since the same quarter in the previous year.
Finally, its free cash flow fell by 33.4% to $-6M since the same quarter in the previous year.
Based on the above factors, Adamis Pharmaceuticals Corporation gets an overall score of 2/5.